Back to diagnoses

What is schizophrenia?

Schizophrenia is a psychotic disorder characterized by positive symptoms like delusions and hallucinations, and negative symptoms like avolition and alogia. It occurs in 1% of the population worldwide. There are no gender differences in the prevalence of schizophrenia, but the incidence of first-episode psychosis in men most likely occurs between ages 18 and 24, whereas in women it is in the late twenties and between ages 50 and 54.

What does schizophrenia look like?

Risk Factors

  • Stresses in the perinatal period, such as starvation, poor nutrition, and infections
  • Childbirth complications
  • Genetics (80% heritability)
  • Low birth weight, short gestation, and early developmental difficulties
  • Central nervous system infections in childhood
  • Advanced paternal age

Prognosis

  • 5-13% of individuals with schizophrenia die by suicide
  • Cognitive deficits in attention, processing speed, and executive function
  • Factors associated with good prognosis: late or acute onset, obvious precipitating factors, good pre-morbid social functioning, a family history of mood disorders, married, strong support systems, positive symptoms
  • Factors associated with poor prognosis: young or insidious age of onset, lack of obvious precipitating factors, poor pre-morbid social functioning, withdrawn behaviors, isolation, family history, negative symptoms, neurological signs and symptoms, history of perinatal trauma, lack of remission, recurrent relapses, and history of violence/assault
  • Only 13% of individuals with schizophrenia meet the criteria for recovery

Differential Diagnosis

  • Brief psychotic disorder
  • Schizophreniform disorder
  • Schizoaffective disorder
  • Autoimmune encephalitis

The dopamine hypothesis:

  • An increase in dopamine activity causes the positive symptoms of schizophrenia
  • Antipsychotics target the mesolimbic pathway and bind to dopaminergic neuroreceptors to decrease the incidence of positive symptoms

Neuroimaging findings:

  • Ventricular enlargement
  • Reduced hippocampus, parahippocampal gyrus, and amygdala volume
  • Reduced grey matter volume
  • Neuronal loss in the medial thalamus
  • Hypoactivity of dorsolateral prefrontal cortex

Influenza:

  • Association between influenza and psychosis has been seen since the early 1700s
  • Population studies show that individuals born in winter and spring are at higher risk for schizophrenia compared to those born in summer and autumn
  • Psychosis is thought to be linked to processes such as maternal immune activation, disruption of cytokine networks, and microglial activation of pathogenic processes that lead to schizophrenia

Degenerative disease model:

  • Increase in research studies suggesting that schizophrenia is not a progressive disorder, and that neuropsychological function can remain stable over time
  • There is minimal evidence that untreated psychosis damages brain structures
  • Individuals with schizophrenia can achieve a stable remission of symptoms as well as satisfaction and happiness

    How is schizophrenia investigated?

    • Labwork: CBC, electrolytes, creatinine, GFR, macroprolactin, prolactin, inflammatory markers, TSH, T3, T4, lead level, infectious diseases (HIV, Hep A/B/C, syphillis), metabolic screen (HBA1c, LDL, HDL, total cholesterol, triglycerides)
    • Urine drug screen
    • Neuroimaging if there is rapid progression of cognitive and memory deficits alongside psychotic symptoms, or if there are indicators pointing to autoimmune encephalitis
    • Genetic testing for those with intellectual disability, developmental delay, and/or multiple congenital abnormalities
    • Cognitive testing for first-episode psychosis or those with poor treatment response

    Positive and Negative Syndrome Scale (PANSS)

    • Clinician rater
    • 45-minute clinical interview where the patient is rated on 30 different symptoms on a scale on a 7-point scale

    Brief Psychiatric Rating Scale (BPRS)

    • Clinician rater
    • 24 symptom constructs rated on a 7-point scale

    Calgary Depression Scale for Schizophrenia (CDSS)

    • Clinician rater
    • 9-item scale measuring the level of depression in individuals with schizophrenia

    How is schizophrenia treated?

    • Antipsychotics are the gold standard medication for treating schizophrenia
    • There is no evidence for antipsychotic polypharmacy for schizophrenia
    • First-generation (typical) antipsychotics
      • Haloperidol (Haldol)
      • Flupentixol (Fluanxol)
      • Loxapine (Loxapac)
      • Zuclopenthixol (Clopixol)
      • Chlorpromazine (Thorazine)
      • Methotrimeprazine (Nozinan)
      • Fluphenazine (Modecate/Prolixin)
      • Perphenazine (Trilafon)
    • Second-generation (atypical) antipsychotics
      • Risperidone (Risperdal)
      • Paliperidone (Invega)
      • Aripiprazole (Abilify)
      • Brexpiprazole (Rexulti)
      • Ziprasidone (Zeldox/Geodon)
      • Lurasidone (Latuda)
      • Quetiapine (Seroquel)
      • Clozapine (Clozaril)

    Special Considerations

    Children & Teenagers

    Aripiprazole (Abilify) and lurasidone (Latuda) are the only antipsychotics indicated for children and adolescents with schizophrenia.

    Older Adults

    Late-onset schizophrenia is the onset of schizophrenia after age 60, and is usually associated with fewer negative symptoms and less severe neurocognitive impairments. Hallucinations can be more prominent. Partition delusions (belief that people and objects can pass through impermeable barriers and enter their homes with harmful intent) is more common in late-onset schizophrenia.

    There is an increased risk of developing dementia for those who experience late-onset schizophrenia.

    Nursing Management

    Causes & Behaviors:

    • Responding to internal stimuli; mumbling to self, talking or laughing to self
    • Inappropriate responses
    • Disorientation to person/place/time
    • Tilting the head as if listening to someone
    • Change in problem-solving pattern
    • Change in communication pattern

    Interventions:

    • Acknowledge the client's experience but explain that you don't hear the voices
    • Be alert for signs of increasing fear, anxiety, or agitation
    • Help the client identify needs that might underlie the hallucination
    • Decrease environmental stimuli to decrease the potential for anxiety that might trigger hallucinations
    • Offer medication when indicated
    • Promote the exploration of activities as distraction from the hallucinations
    • Engage the client in reality-based activities

    [1] Abel, K. M., Drake, R., & Goldstein, J. M. (2010). Sex differences in schizophrenia. International Review of Psychiatry, 22(5), 417-428.

    [2] Anderson, K. K., Rodrigues, M., Mann, K., Voineskos, A., Mulsant, B. H., George, T. P., & McKenzie, K. J. (2015). Minimal evidence that untreated psychosis damages brain structures: A systematic review. Schizophrenia Research162(1-3), 222–233.

    [3] American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA.

    [4] Boyd, M. A. (2019). Psychiatric & mental health nursing for Canadian practice. Wolters Kluwer.

    [5] Masi, G., & Liboni, F. (2011). Managemnet of schizophrenia in children and adolescents: Focus on pharmacology. Drugs, 71(2), 179-208.

    [6] Townsend, M. C. (2015). Psychiatric mental health nursing. F.A. Davis.

    [7] Zaheer, J., Olfson, M., Mallia, E., Lam, J. S. H., de Oliveira, C., Rudoler, D., Carvalho, A. F., Jacob, B. J., Juda, A., & Kurdyak, P. (2020). Predictors of suicide at time of diagnosis in schizophrenia spectrum disorder: A 20-year total population study in Ontario, Canada. Schizophrenia research222, 382–388.

    [8] Zipursky, R. B., & Agid, O. (2015). Recovery, not progressive deterioration, should be the expectation in schizophrenia. World Psychiatry: Official journal of the World Psychiatric Association (WPA)14(1), 94–96.